General Announcement::Approval of Clinical Trials for Vitiligo and Hidradenitis Suppurativa Indications of Povorcitinib

Issuer & Securities

Issuer/ Manager
CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Securities
CHINA MEDICAL SYSTEM HLDGS LTD - KYG211081248 - 8A8
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
28-Aug-2025 20:14:35
Status
New
Announcement Sub Title
Approval of Clinical Trials for Vitiligo and Hidradenitis Suppurativa Indications of Povorcitinib
Announcement Reference
SG250828OTHRUXXK
Submitted By (Co./ Ind. Name)
Wu Sanyan
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please refer to the attachment.

Attachments

CMS - Ann - Approval of Clinical Trials for Vitiligo and Hidradenitis_28Aug2025.pdf
Total size =171K